27 Recruiting Studies Using Elranatamab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Elranatamab
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
📍 Beverly Hills Cancer Center — Beverly Hills, California
Multiple Myeloma
View Study & Checklist ➔A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Multiple Myeloma
View Study & Checklist ➔Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
📍 Banner Gateway Medical Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma (MM)
View Study & Checklist ➔Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
📍 UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California
Multiple Myeloma
View Study & Checklist ➔Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
📍 Vancouver Cancer Center — Vancouver, British Columbia
Refractory Multiple Myeloma
View Study & Checklist ➔ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
📍 University of Miami — Miami, Florida
Multiple Myeloma
View Study & Checklist ➔A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
📍 Jupiter Medical Center/Anderson Family Cancer Institute — Jupiter, Florida
Multiple Myeloma
View Study & Checklist ➔Elranatamab in R/R Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Refractory Multiple Myeloma
View Study & Checklist ➔A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
📍 Colorado Blood Cancer Institute — Denver, Colorado
Multiple Myeloma (MM)
View Study & Checklist ➔A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
📍 MD Anderson Cancer Center — Houston, Texas
Phase 2
View Study & Checklist ➔A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
📍 Research Site — Duarte, California
Multiple Myeloma
View Study & Checklist ➔Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
📍 MD Anderson Cancer Center — Houston, Texas
Multiple Myeloma
View Study & Checklist ➔Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Haematological Malignancy
View Study & Checklist ➔A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
📍 Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida
Multiple Myeloma
View Study & Checklist ➔Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma, Newly Diagnosed
View Study & Checklist ➔Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
📍 Moffitt Cancer Center — Tampa, Florida
Myeloma
View Study & Checklist ➔A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
📍 Clovis Community Medical Center — Clovis, California
Multiple Myeloma
View Study & Checklist ➔Elranatamab in Relapsed/Refractory Multiple Myeloma
📍 University of California San Diego — La Jolla, California
Multiple Myeloma
View Study & Checklist ➔A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔ELISA in Relapsed/Refractory MM
📍 Massachusetts General Hospital — Boston, Massachusetts
Relapsed Refractory Multiple Myeloma (RRMM)
View Study & Checklist ➔A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Multiple Myeloma
View Study & Checklist ➔Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
📍 Yale University — New Haven, Connecticut
AL Amyloidosis
View Study & Checklist ➔MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
📍 Infirmary Cancer Care — Mobile, Alabama
Multiple Myeloma
View Study & Checklist ➔